Basic Info
  • Grade: pharmaceutical grade

    Factory Location: Shanghai

    Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Eastern Europe,Australasia,Asia,Middle East,Africa

  • Sample Provided: no

    Laratinib is a third-generation ALK tyrosine kinase inhibitor (TKI) suitable for treating ALK positive metastatic non-small cell lung cancer (NSCLC) patients whose disease has progressed prior to a) treatment with clotozantinib and at least one other ALK inhibitor. Or b) previously used erlotinib as the first ALK inhibitor for treating metastatic diseases, or c) previously used clotozantinib as the first ALK inhibitor for treating metastatic diseases.
Send your message to this supplier
  • From:
  • To:
    Shanghai Hope-chem Co.,Ltd.
  • Send a Copy to this Email
  • Message:
    Upload Images / Files
    - Supports jpg, jpeg, png,
     gif, pdf, doc, docx,
     xls, xlsx, txt, rar and zip
    - Max upload 3 files;
     Max  total size: 3MB
    (0/3)

    Enter between 20 to 4,000 characters.This is not what you are looking for ? Post a Sourcing Request Now

  • Verification:
PharmaSources Customer Service